Eledon Pharmaceuticals, Inc. (ELDN) — SEC Filings
Eledon Pharmaceuticals, Inc. (ELDN) — 34 SEC filings. Latest: 8-K (Nov 14, 2025). Includes 16 8-K, 4 SC 13G/A, 3 10-K/A.
View Eledon Pharmaceuticals, Inc. on SEC EDGAR
Overview
Eledon Pharmaceuticals, Inc. (ELDN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 14, 2025: Eledon Pharmaceuticals, Inc. filed an 8-K on November 14, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company was formerly known as Novus Therapeutics, Inc. and Tokai Pharmaceuticals Inc.
Sentiment Summary
Across 34 filings, the sentiment breakdown is: 1 bullish, 32 neutral, 1 mixed. The dominant filing sentiment for Eledon Pharmaceuticals, Inc. is neutral.
Filing Type Overview
Eledon Pharmaceuticals, Inc. (ELDN) has filed 16 8-K, 3 10-K/A, 3 10-Q, 2 DEF 14A, 1 8-K/A, 2 10-K, 4 SC 13G/A, 3 SC 13G with the SEC between Feb 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (34)
Risk Profile
Risk Assessment: Of ELDN's 26 recent filings, 0 were flagged as high-risk, 19 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Key Executives
- Dr. Jonathan T. Hunt
- Dr. David M. Epstein
Industry Context
Eledon Pharmaceuticals operates in the highly competitive and rapidly evolving biotechnology sector, focusing on novel therapies for significant unmet medical needs like organ transplant rejection and ALS. The industry is characterized by long development cycles, high R&D costs, and stringent regulatory hurdles. Success often hinges on scientific innovation, robust clinical trial data, and securing substantial funding.
Top Tags
financial-reporting (4) · material-definitive-agreement (3) · corporate-governance (3) · 10-Q (3) · pharmaceuticals (3) · auditor-change (3) · Eledon Pharmaceuticals (3) · corporate-actions (2) · SEC Filing (2) · financials (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Market value of common stock held by non-affiliates | $64,885,717 | As of June 30, 2024 |
| Shares of Common Stock outstanding | 59,881,775 | As of August 13, 2025 |
| Fiscal year ended | 2024 | Financial statements restated |
| Filing date of 10-K/A | 2025-08-14 | Date of amendment |
| Filing date of Original Report | 2025-03-20 | Date of initial 10-K filing |
| SEC File Number | 001-36620 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 20-1000967 | Company's tax identification number. |
| Reporting Period | Q1 2025 | First quarter of 2025 |
| Fiscal Period End | 20250331 | End date for the reported period |
| Equity Award Years | 2022-2024 | Covers executive equity awards granted and valued over these fiscal years. |
| Filing Date | 20250429 | Date the DEF 14A was officially submitted to the SEC. |
| Reporting Period End Date | 20240930 | Indicates the end of the fiscal quarter for which financial information is reported. |
| Securities Purchase Agreement Second Closing | 2024-07-08 | Marks a significant financing event for the company. |
| Securities Purchase Agreement Initial Closing | 2023-05-05 | Marks an earlier significant financing event for the company. |
| Fiscal Year End | 20231231 | The period covered by the annual report. |
Frequently Asked Questions
What are the latest SEC filings for Eledon Pharmaceuticals, Inc. (ELDN)?
Eledon Pharmaceuticals, Inc. has 34 recent SEC filings from Feb 2024 to Nov 2025, including 16 8-K, 4 SC 13G/A, 3 10-K/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ELDN filings?
Across 34 filings, the sentiment breakdown is: 1 bullish, 32 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Eledon Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Eledon Pharmaceuticals, Inc. (ELDN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Eledon Pharmaceuticals, Inc.?
Key financial highlights from Eledon Pharmaceuticals, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ELDN?
The investment thesis for ELDN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Eledon Pharmaceuticals, Inc.?
Key executives identified across Eledon Pharmaceuticals, Inc.'s filings include Dr. Jonathan T. Hunt, Dr. David M. Epstein.
What are the main risk factors for Eledon Pharmaceuticals, Inc. stock?
Of ELDN's 26 assessed filings, 0 were flagged high-risk, 19 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Eledon Pharmaceuticals, Inc.?
Forward guidance and predictions for Eledon Pharmaceuticals, Inc. are extracted from SEC filings as they are enriched.